Precocious Puberty, Central
1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
UNION therapeuticsDenmark - Hellerup
1 programMulti-Component Behavioral interventionN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
TolmarLeuprolide Acetate 45 mg
UNION therapeuticsMulti-Component Behavioral intervention
Clinical Trials (2)
Total enrollment: 764 patients across 2 trials
Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty
Start: Aug 2015Est. completion: Sep 201864 patients
Phase 3Completed
Hypiend - Multicomponent Behavioral Intervention in Pre-puberal Children (Hypiend-PPC)
Start: Sep 2025Est. completion: Dec 2028700 patients
N/AActive Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.